Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren-GETUG AFU 26 trial.

被引：0
|
作者：
Colomba, Emeline [1 ]
Flippot, Ronan [2 ]
Dalban, Cecile [3 ]
Negrier, Sylvie [4 ]
Chevreau, Christine [5 ]
Gravis, Gwenaelle [6 ]
Oudard, Stephane [7 ]
Laguerre, Brigitte [8 ]
Barthelemy, Philippe [9 ]
Goupil, Marine Gross [10 ]
Geoffrois, Lionnel [11 ]
Rolland, Frederic [12 ]
Thiery-Vuillemin, Antoine [13 ]
Joly, Florence [14 ]
Ladoire, Sylvain [15 ]
Tantot, Florence [16 ]
Escudier, Bernard [17 ]
Albiges, Laurence [18 ]
机构：
[1] Paris Saclay Univ, Gustave Roussy Canc Campus, Villejuif, France
[2] Gustave Roussy, Dept Med Oncol, Villejuif, France
[3] Ctr Leon Berard, Lyon, France
[4] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[5] IUCT Oncopole Inst Claudius Regaud, Toulouse, France
[6] Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France
[7] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Oncol, Paris, France
[8] Ctr Eugene Marquis, Rennes, France
[9] Inst Cancerol Strasbourg Europe, Strasbourg, France
[10] CHU Bordeaux, Bordeaux, France
[11] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[12] Inst Cancerol Ouest, Dept Med Oncol, St Herblain, France
[13] Univ Hosp Jean Minjoz, Besancon, France
[14] Ctr Francois Baclesse, Dept Med Oncol, Caen, France
[15] Georges Francois Leclerc Canc Ctr, Dijon, France
[16] UNICANCER, Le Kremlin Bicetre, France
[17] Gustave Roussy, Villejuif, France
[18] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.359
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
359
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A phase II trial of RAD001 in patients (PTS) with metastatic renal cell carcinoma (MRCC)
    Amato, R.
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    CANCER INVESTIGATION, 2007, 25 : 20 - 21
  • [42] Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).
    Plimack, Elizabeth R.
    Hammers, Hans J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce
    Kuzel, Timothy
    Harrison, Michael Roger
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim Allyson
    Xu, Li-an
    Waxman, Ian
    Motzer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC)
    Plimack, Elizabeth R.
    Hammers, Hans J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce G.
    Kuzel, Timothy M.
    Harrison, Michael R.
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim A.
    Xu, Li-An
    Waxman, Ian M.
    Motzer, Robert J.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 129 - 129
  • [44] A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
    Ornstein, Moshe C.
    Wood, Laura S.
    Hobbs, Brian P.
    Allman, Kimberly D.
    Martin, Allison
    Bevan, Michael
    Gilligan, Timothy D.
    Garcia, Jorge A.
    Rini, Brian, I
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [45] Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.
    Ebrahimi, Hedyeh
    Meza, Luis A.
    Lee, Keehoon
    Malhotra, Jasnoor
    Alcantara, Marice
    Zengin, Zeynep Busra
    Dizman, Nazli
    Govindarajan, Ameish
    Hsu, Joann
    Llamas-Quitiquit, Marian
    Chawla, Neal Shiv
    Castro, Daniela V.
    Mercier, Benjamin D.
    Liu, Sandy
    Chehrazi-Raffle, Alex
    Dorff, Tanya B.
    Frankel, Paul Henry
    Li, Xiaochen
    Pal, Sumanta Kumar
    Tripathi, Abhishek
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [46] Phase II study of bortezomib and thalidomide in patients with metastatic renal cell carcinoma (MRCC).
    Amato, R
    Misellati, A
    Marsh, L
    Shen, S
    Jac, J
    Ross, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9121S - 9122S
  • [47] Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC).
    Jac, J
    Hernandez, J
    Phan, SC
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 433S - 433S
  • [48] Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
    Kessler, Elizabeth R.
    Hu, Junxiao
    Srivastava, Geetika
    Kemme, Douglas Jerome
    Iruku, Praveena
    Rana, Vishal
    Schuster, Steven Robert
    Amirault, Mali
    Callihan, Eryn
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
    Lee, Chung-Han
    Voss, Martin H.
    Carlo, Maria Isabel
    Chen, Ying-Bei
    Reznik, Eduard
    Knezevic, Andrea
    Lefkowitz, Robert A.
    Shapnik, Natalie
    Tassone, Diana
    Dadoun, Chloe
    Shah, Neil J.
    Owens, Colette Ngozi
    McHugh, Deaglan Joseph
    Aggen, David Henry
    Laccetti, Andrew Leonard
    Kotecha, Ritesh
    Feldman, Darren R.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.
    Lee, Chung-Han
    Fitzgerald, Kelly N.
    Voss, Martin H.
    Carlo, Maria Isabel
    Knezevic, Andrea
    Peralta, Laura
    Chen, Ying-Bei
    Zucker, Mark
    Lefkowitz, Robert A.
    Reznik, Eduard
    Shah, Neil J.
    Owens, Colette Ngozi
    McHugh, Deaglan Joseph
    Aggen, David H.
    Laccetti, Andrew Leonard
    Kotecha, Ritesh R.
    Feldman, Darren R.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345